Compare HCI & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCI | GRDN |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Retail-Drug Stores and Proprietary Stores |
| Sector | Finance | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2024 |
| Metric | HCI | GRDN |
|---|---|---|
| Price | $162.50 | $34.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $230.00 | $33.33 |
| AVG Volume (30 Days) | 164.2K | ★ 259.8K |
| Earning Date | 02-25-2026 | 03-11-2026 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | ★ 32.29 | N/A |
| EPS | ★ 15.80 | 0.28 |
| Revenue | $816,578,000.00 | ★ $1,389,638,000.00 |
| Revenue This Year | $18.28 | $19.50 |
| Revenue Next Year | $11.03 | N/A |
| P/E Ratio | ★ $10.17 | $122.29 |
| Revenue Growth | 8.75 | ★ 18.68 |
| 52 Week Low | $115.65 | $17.78 |
| 52 Week High | $210.50 | $37.43 |
| Indicator | HCI | GRDN |
|---|---|---|
| Relative Strength Index (RSI) | 46.26 | 65.72 |
| Support Level | $155.77 | $30.85 |
| Resistance Level | $165.22 | $33.00 |
| Average True Range (ATR) | 5.16 | 1.31 |
| MACD | 1.04 | 0.43 |
| Stochastic Oscillator | 67.85 | 93.47 |
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.